Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) — Oct 3rd, 2024

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded indu...

Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 10% this week, taking three-year losses to 86% — Oct 3rd, 2024

It's not possible to invest over long periods without making some bad investments. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Intellia Therapeutics, Inc. (NASDAQ:NTLA); the share price is down a whopping 86% in the ...

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk — Sep 29th, 2024

Portfolio manager Cathie Wood's Ark Innovation ETF(NYSEMKT: ARKK) loaded up on a pair of biotech stocks throughout August and early September, and it wasn't the first time they caught her attention. Her style is to invest in growth businesses that are pursuing disruptive innovation within ...

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions — Oct 1st, 2024

Intellia Therapeutics, Inc. New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR amyloidosis CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE...